Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer

Summary

This phase II trial studies how well lenvatinib works when given together with standard of care iodine I-131 in treating patients with radioactive iodine-sensitive differentiated thyroid cancer. Lenvatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2019-01-16

Primary completion

2021-06-24

Completion

2021-06-24

Outcome

Outcome not reported

Stopped (Enrollment): “Study has been abandoned for lack of accrual”

Drugs

Indications